Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 5/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3567448 | 0.93 | GSK3B (0.40) | LARS1BCL2L1MCL1PTGES2PPARG | |
| SCHEMBL3571663 | 0.90 | BCL2L1 (0.39) | LARS1BCL2L1MCL1PTGES2PFKFB3 | |
| SCHEMBL3565927 | 0.90 | CA2 (0.41) | LARS1BCL2L1MCL1PTGES2PFKFB3 | |
| SCHEMBL3562257 | 0.88 | LARS1 (0.45) | LARS1BCL2L1MCL1PTGES2PFKFB3 | |
| SCHEMBL3563476 | 0.87 | PTGES2 (0.41) | PTGES2PFKFB3HSD11B1NR1H2S1PR1 | |
| SCHEMBL3569720 | 0.86 | NR1H2 (0.48) | PTGES2PFKFB3HSD11B1CA1CA2 | |
| SCHEMBL3565170 | 0.84 | SYK (0.43) | PTGES2PFKFB3FLT3S1PR1S1PR3 | |
| SCHEMBL3557260 | 0.84 | IDH2 (0.41) | PTGES2PFKFB3HSD11B1NR1H2 | |
| SCHEMBL3566785 | 0.84 | PTGES2 (0.44) | PTGES2PFKFB3HSD11B1CA1CA2 | |
| SCHEMBL3566492 | 0.84 | KIF18A (0.44) | LARS1PTGES2PFKFB3HSD11B1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001849-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | claimed |
| EP-2468727-A1 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | claimed |
| US-8183262-B2 | Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | claimed |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GATTI MCARTHUR SILVIA | 2009-12-24 | — | — | US | claimed |
| EP-2001849-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | claimed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | claimed |
| WO-2007110337-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | claimed |
| US-20190343839-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | HOFFMANN-LA ROCHE INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20170173022-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF AUTISTIC DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173022-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF AUTISTIC DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170035767-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170035767-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-09 | — | — | US | disclosed |
| WO-2015162076-A2 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-29 | — | — | WO | disclosed |
| EP-2468727-A1 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8183262-B2 | Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-7642264-B2 | Phenyl-substituted pyrimidine derivatives as mGluR antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GATTI MCARTHUR SILVIA | 2009-12-24 | — | — | US | disclosed |
| EP-2001849-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007110337-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035767-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | GRM2, GRM3, GRIK2 | LARS1 3901/4885BCL2L1 4307/4885MCL1 4258/4885 |
| US-20190343839-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | GRM2, GRM3, GRM5 | LARS1 4113/4885BCL2L1 4468/4885MCL1 4423/4885 |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | P2RX2, P2RY2, P2RX1 | LARS1 4547/4885BCL2L1 4568/4885MCL1 3162/4885 |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GRM2, GRM1, GRM3 | LARS1 4085/4885BCL2L1 4214/4885MCL1 4340/4885 |
| US-20170173022-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF AUTISTIC DISORDERS | GRM2, GRM3, GRM5 | LARS1 4273/4885BCL2L1 4682/4885MCL1 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.